CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Multiple myeloma (MM) treatments have improved survival, but drug resistance and disease progression, including extramedullary disease, remain challenges.
• Identifying key drivers of MM progression is crucial for developing more effective therapies.

Purpose of the Study:

• To investigate the role of CD70-expressing myeloma cells in MM progression.
• To elucidate the mechanisms by which CD70 contributes to MM pathogenesis.
• To evaluate therapeutic strategies targeting the CD70/CD27 axis.

Main Methods:

• Analysis of CD70 expression in MM patient samples and correlation with survival.
• Investigating CD70/CD27 signaling pathways (MAPK/ERK, Wnt) in MM cell lines and primary samples.
• Functional studies using CD70-knockout cells and blocking antibodies in xenotransplantation models.
• Assessment of cusatuzumab (ADCC-enhanced anti-CD70 antibody) efficacy in vivo.

Main Results:

• CD70 expression in MM cells is an independent negative prognostic factor for overall survival.
• CD70/CD27 signaling activates MAPK/ERK and Wnt pathways, promoting MM cell proliferation.
• Elevated CD70 expression is observed in advanced MM stages and extramedullary disease.
• Inhibition of CD70/CD27 signaling abrogated tumor growth in xenotransplantation models.
• Cusatuzumab demonstrated significant efficacy in treating MM xenografts.

Conclusions:

• CD70-expressing myeloma cells are critical drivers of MM progression and propagation.
• Targeting CD70/CD27 signaling, particularly with antibodies like cusatuzumab, is a promising therapeutic strategy for MM, especially in advanced stages.